pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,307 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT807Endpoints607BioPharma Dive231onclive165Fierce Biotech74BioSpace72raps32fda press20fda medwatch
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
    Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.
    BioPharma Dive · 28d ago↗ source
  • Beeline ups its Series A round for immune drug work
    The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
    BioPharma Dive · 28d ago↗ source
  • STAT+: All of Us tests a new approach to collect real-world data for research
    The NIH All of Us Research Program has secured thousands of electronic medical records through an innovative use of patient data-sharing networks
    STAT · 28d ago↗ source
← prev
page 19 of 53
next →
20
globenewswire health20
fda recalls16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Top FDA gene and cell therapy regulator to step down
    Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
    BioPharma Dive · 28d ago↗ source
  • STAT+: Investors double down on Bain-backed startup
    FDA's top gene therapy regulator steps down, Trump's plan to lower GLP-1 prices, and more biotech news
    STAT · 28d ago↗ source
  • STAT+: FDA digital leader hints at coming AI policy updates
    Today's health tech news includes virtual PT for a whole country, what the FDA is considering on AI policy, and more
    STAT · 28d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Chinese trial sites being probed, RFK Jr. and peptides, and more
    U.S. lawmakers are investigating whether several large drugmakers have been involved ​in clinical trials in China that helped fuel its military capability
    STAT · 28d ago↗ source
  • Half of states sue over Medicaid work requirements
    FDA peptide panelists, a new study on Covid and flu shots, and more health news from Morning Rounds
    STAT · 29d ago↗ source
  • STAT+: Even with MAHA, Trump administration has gone soft on alcohol
    A STAT investigation has found that the Trump administration has downplayed alcohol’s risks and actively derailed efforts to understand and prevent drinking-related harms.
    STAT · 29d ago↗ source
  • Opinion: Florida is the first state to require EKGs for high school athletes. It’s a mistake
    “There are better ways for schools to protect student athletes,” writes Katherine Hofmann.
    STAT · 29d ago↗ source
  • STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
    The Trump administration's grand bargain with drugmakers isn't working out as planned.
    STAT · 29d ago↗ source
  • Opinion: Short-sighted new student loan caps elevate chiropractic care over critical health care professions
    “This administrative logic is hopelessly out of touch with the empirical reality of American health care,” writes David S. Shapiro.
    STAT · 29d ago↗ source
  • STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
    Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
    STAT · 29d ago↗ source
  • STAT+: FDA’s top gene therapy regulator is leaving his role
    The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
    STAT · 29d ago↗ source
  • STAT+: AstraZeneca to pay $34 million to settle kickback charges filed by Texas attorney general
    AstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks to improperly influence prescriptions paid for by Texas Medicaid.
    STAT · 29d ago↗ source
  • STAT+: 26 states sue to block Medicaid work requirements
    States argue the rules will make it too hard for people to get the Medicaid coverage they're entitled too.
    STAT · 29d ago↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 29d ago↗ source
  • STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a ‘forced’ McKinsey collaboration
    Who controls the Medicaid market, GLP-1 usage and pizza household costs, and more from Health Care Inc.
    STAT · 29d ago↗ source
  • STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
    The panel will soon consider whether to relax restrictions on certain peptides.
    STAT · 29d ago↗ source
  • Theravance, after clinical setbacks, agrees to $929M buyout
    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
    BioPharma Dive · 29d ago↗ source
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    BioPharma Dive · 1mo ago↗ source
  • FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
    BioPharma Dive · 1mo ago↗ source
  • At BIO, tension over China biotech deal regulation looms
    Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
    BioPharma Dive · 1mo ago↗ source
  • Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
    Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
    BioPharma Dive · 1mo ago↗ source
  • On second try, Acadia drug gets nod from European regulators
    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
    BioPharma Dive · 1mo ago↗ source